Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Selected Balance Sheet Data

v3.20.2
Note 3 - Selected Balance Sheet Data
3 Months Ended
Sep. 30, 2020
Notes to Financial Statements  
Supplemental Balance Sheet Disclosures [Text Block]

Note 3. Selected Balance Sheet Data:

 

Inventories:

 

Inventories consist of (in thousands):

 

   

September 30,

   

June 30,

 
   

2020

   

2020

 

Raw materials

  $ 52,808     $ 51,530  

Finished goods(1)

    57,887       56,268  

Inventories, net

  $ 110,695     $ 107,798  

 

(1) Finished goods inventory of $4,692 and $4,646 included within other long-term assets in the respective September 30, 2020 and June 30, 2020, consolidated balance sheet. The inventory is included in long-term assets as it is forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.  

 

Property and Equipment:

 

Property and equipment consist of (in thousands):

 

   

September 30,

   

June 30,

 
   

2020

   

2020

 

Land

  $ 8,536     $ 8,516  

Buildings and improvements

    185,606       184,430  

Machinery and equipment

    172,955       153,704  

Property and equipment, cost

    367,097       346,650  

Accumulated depreciation and amortization

    (175,420

)

    (169,821

)

Property and equipment, net

  $ 191,677     $ 176,829  

 

Intangible Assets:

 

Intangible assets consist of (in thousands):

 

   

September 30,

   

June 30,

 
   

2020

   

2020

 

Developed technology

  $ 435,761     $ 434,653  

Trade names

    143,926       146,713  

Customer relationships

    213,769       211,750  

Patents and other intangibles(1)

    8,138       2,475  

Intangible assets

    801,594       795,591  

Accumulated amortization

    (294,003

)

    (279,046

)

Intangible assets, net

  $ 507,591     $ 516,545  

 

(1) Increase in patents and other intangible assets is primarily due to $5.0 million recognized in intangible assets in the first quarter of fiscal 2021 for certain third party patented technology acquired. The $5.0 million for the third party patented technology acquired was a non-cash activity within the condensed consolidated statement of cash flows as a cash payment was not made within the fiscal quarter. 

 

Changes to the carrying amount of net intangible assets for the quarter ended September 30, 2020 consist of (in thousands):

 

Beginning balance

  $ 516,545  

Acquisitions

    -  

Other additions

    5,135  

Amortization expense

    (15,575

)

Currency translation

    1,486

 

Ending balance

  $ 507,591  

 

The estimated future amortization expense for intangible assets as of September 30, 2020 is as follows (in thousands):

 

2021 remainder

  $ 44,908  

2022

    58,326  

2023

    56,447  

2024

    53,892  

2025

    50,698  

Thereafter

    243,320  

Total

  $ 507,591  

 

Goodwill:

 

Changes to the carrying amount of goodwill for the quarter ended September 30, 2020 consist of (in thousands):

 

   

Protein Sciences

   

Diagnostics and

Genomics

   

Total

 

Beginning balance

  $ 373,081       355,229     $ 728,310  

Currency translation

    3,211

 

    115

 

    3,326

 

Ending balance

  $ 376,292     $

355,344

    $ 731,636  

 

We evaluate the carrying value of goodwill in the fourth quarter of each fiscal year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. The Company performed a goodwill impairment assessment for all of its reporting units during the fourth quarter of fiscal 2020. No indicators of impairment were identified as part of our assessment. 

 

No triggering events were identified during the quarter ended September 30, 2020. There has been no impairment of goodwill since the adoption of Financial Accounting Standards Board (“FASB”) ASC 350 guidance for goodwill and other intangibles on July 1, 2002.